Correlation Between Lantern Pharma and UroGen Pharma

Can any of the company-specific risk be diversified away by investing in both Lantern Pharma and UroGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lantern Pharma and UroGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lantern Pharma and UroGen Pharma, you can compare the effects of market volatilities on Lantern Pharma and UroGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lantern Pharma with a short position of UroGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lantern Pharma and UroGen Pharma.

Diversification Opportunities for Lantern Pharma and UroGen Pharma

-0.31

Correlation Coefficient

Lantern Pharma  UroGen Pharma

Very good diversification

The 3 months correlation between Lantern and UroGen is -0.31. Overlapping area represents the amount of risk that can be diversified away by holding Lantern Pharma and UroGen Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UroGen Pharma and Lantern Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lantern Pharma are associated (or correlated) with UroGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UroGen Pharma has no effect on the direction of Lantern Pharma i.e., Lantern Pharma and UroGen Pharma go up and down completely randomly.

Pair Corralation between Lantern Pharma and UroGen Pharma

Given the investment horizon of 90 days Lantern Pharma is expected to generate 2.89 times more return on investment than UroGen Pharma. However, Lantern Pharma is 2.89 times more volatile than UroGen Pharma. It trades about 0.08 of its potential returns per unit of risk. UroGen Pharma is currently generating about -0.19 per unit of risk. If you would invest  316.00  in Lantern Pharma on December 1, 2024 and sell it today you would earn a total of  79.00  from holding Lantern Pharma or generate 25.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Lantern Pharma  vs.  UroGen Pharma

Lantern Pharma

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Lantern Pharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Lantern Pharma displayed solid returns over the last few months and may actually be approaching a breakup point.

UroGen Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Lantern Pharma and UroGen Pharma

The main advantage of trading using opposite Lantern Pharma and UroGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lantern Pharma position performs unexpectedly, UroGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will offset losses from the drop in UroGen Pharma's long position.

The idea behind Lantern Pharma and UroGen Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..